Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
November 19, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
November 18, 2024 11:00 ET
|
Siren Biotechnology, Inc.
Siren Biotechnology reveals SRN-101 as lead asset for high-grade gliomas with both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting
November 14, 2024 03:30 ET
|
Vivet Therapeutics
Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting Gene therapy...
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 12, 2024 16:05 ET
|
Fractyl Health, Inc.
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
November 08, 2024 06:45 ET
|
Ocugen
Subsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025OCU410 is currently in...
Cell And Gene Therapy Market Size to Worth USD 190.82 Billion by 2033 | Straits Research
November 07, 2024 09:30 ET
|
Straits Research Private Limited - Garner Insights
New York, United States , Nov. 07, 2024 (GLOBE NEWSWIRE) -- “Cell therapy” refers to the process of administering live cells to patients with the purpose of treating various diseases. Both...
Ocugen Secures $30 Million in Debt Funding
November 07, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
November 05, 2024 07:05 ET
|
uniQure Inc.
~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington’s disease ~ ~...
Cell and Gene Therapy CRO Market Research Trends and Global Forecasts, 2024-2035: Over 105 CROs Drive Innovation, with 80% Ensuring Comprehensive Support from R&D to Clinical Trials
November 04, 2024 05:40 ET
|
Research and Markets
Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification,...
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 30, 2024 06:14 ET
|
Lexeo Therapeutics
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's